226 related articles for article (PubMed ID: 35193630)
1. Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers.
Osman SOS; Fairmichael C; Whitten G; Lundy GS; Wesselman R; Wilson ML; Hounsell AR; Prise KM; Irvine D; McGarry CK; Jain S
Radiat Oncol; 2022 Feb; 17(1):38. PubMed ID: 35193630
[TBL] [Abstract][Full Text] [Related]
2. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a rectal spacer with prostate SABR-first UK experience.
King RB; Osman SO; Fairmichael C; Irvine DM; Lyons CA; Ravi A; O'Sullivan JM; Hounsell AR; Mitchell DM; McGarry CK; Jain S
Br J Radiol; 2018 Feb; 91(1083):20170672. PubMed ID: 29182384
[TBL] [Abstract][Full Text] [Related]
4. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
Ruggieri R; Naccarato S; Stavrev P; Stavreva N; Fersino S; Giaj Levra N; Mazzola R; Mancosu P; Scorsetti M; Alongi F
Br J Radiol; 2015 Oct; 88(1054):20140736. PubMed ID: 26235142
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study.
Kim YJ; Yoon KJ; Kim YS
Sci Rep; 2020 Sep; 10(1):14713. PubMed ID: 32895442
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
[TBL] [Abstract][Full Text] [Related]
7. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
[TBL] [Abstract][Full Text] [Related]
8. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer.
Ahmad Khalil D; Jazmati D; Geismar D; Wulff J; Bäumer C; Kramer PH; Steinmeier T; Schulze Schleitthoff S; Plaude S; Bischoff M; Tschirdewahn S; Hadaschik B; Timmermann B
Radiat Oncol; 2022 Apr; 17(1):64. PubMed ID: 35365170
[TBL] [Abstract][Full Text] [Related]
10. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
11. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
12. Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy.
Saito M; Suzuki T; Sugama Y; Marino K; Sano N; Komiyama T; Aoki S; Maehata Y; Yoshizawa K; Ashizawa K; Suzuki H; Ueda K; Miyasaka Y; Araya M; Takahashi H; Onishi H
J Radiat Res; 2020 May; 61(3):487-493. PubMed ID: 32211861
[TBL] [Abstract][Full Text] [Related]
13. Experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion.
Abdellatif A; Craig J; Jensen M; Mulligan M; Mosalaei H; Bauman G; Chen J; Wong E
Med Phys; 2012 Mar; 39(3):1505-17. PubMed ID: 22380383
[TBL] [Abstract][Full Text] [Related]
14. Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer.
Slevin F; Thompson CM; Speight R; Murray LJ; Lilley J; Henry AM
Med Dosim; 2021 Winter; 46(4):411-418. PubMed ID: 34148727
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer.
Riou O; Regnault de la Mothe P; Azria D; Aillères N; Dubois JB; Fenoglietto P
J Appl Clin Med Phys; 2013 Jul; 14(4):4094. PubMed ID: 23835376
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).
Nicolae A; Davidson M; Easton H; Helou J; Musunuru H; Loblaw A; Ravi A
Radiat Oncol; 2015 May; 10():122. PubMed ID: 26024900
[TBL] [Abstract][Full Text] [Related]
17. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
[TBL] [Abstract][Full Text] [Related]
18. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study.
Weber DC; Zilli T; Vallee JP; Rouzaud M; Miralbell R; Cozzi L
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e311-8. PubMed ID: 22999271
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric Uncertainties in Dominant Intraprostatic Lesion Simultaneous Boost Using Intensity Modulated Proton Therapy.
Zhou J; Yang X; Chang CW; Tian S; Wang T; Lin L; Wang Y; Janopaul-Naylor JR; Patel P; Demoor JD; Bohannon D; Stanforth A; Eaton B; McDonald MW; Liu T; Patel SA
Adv Radiat Oncol; 2022; 7(1):100826. PubMed ID: 34805623
[TBL] [Abstract][Full Text] [Related]
20. Dose differentiated high-dose-rate prostate brachytherapy: a feasibility assessment of MRI-guided dose escalation to dominant intra-prostatic lesions.
Luminais CK; Nourzadeh H; Aliotta E; Ward K; Cousins D; Showalter TN; Libby B
J Contemp Brachytherapy; 2022 Oct; 14(5):423-428. PubMed ID: 36478705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
